In 2023, Consun Pharmaceutical Group completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 1 (direct emissions from owned or controlled sources) and Scope 2 (indirect emissions from purchased energy).
However, Consun Pharmaceutical Group has not published a category-level breakdown of its Scope 3 emissions, limiting visibility into specific value chain sources.
| Metric (tCO2e) | 2023 | 2022 | 2021 | 2020-2019 |
|---|---|---|---|---|
Total Scope 1 | 54,210.46a | 53,214.68a | 52,549.12a | |
Total Scope 2 | ||||
Unspecified Calculation Method | 24,914.76a | 18,842.52a | 18,602.09a | |
Total Scope 3 | N/A | N/A | N/A | |
Total Scope 1 Revenue Intensity (tCO2e/$M) | 148.7477a | 158.3737a | 163.7672a |
You are welcome to quote or reference individual data points from this page, provided you include the following attribution with a visible, clickable link to this page: "Source: Tracenable, the global reference for ESG data"
Bulk collection, scraping, resale, or redistribution of data across multiple company profiles is not permitted without our prior written permission. For more information, see our General Terms and Conditions.
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform.
In 2023, the total operational greenhouse gas (GHG) emissions of Consun Pharmaceutical Group amounted to 79,125.22 metric tons of CO2 equivalent. This figure includes both direct emissions from owned or controlled sources (Scope 1) and indirect emissions from purchased energy (Scope 2).a
Compared to 2022, the total operational greenhouse gas (GHG) emissions of Consun Pharmaceutical Group increased by 9.81%, suggesting that the company faced challenges in reducing its emissions from its core operations.a
In 2023, the total Scope 1 emissions of Consun Pharmaceutical Group were 54,210.46 metric tons of CO₂ equivalent (tCO₂e).a
Since 2020, Consun Pharmaceutical Group's Scope 1 emissions have increased by 230.17%, reflecting a rising long-term trend in Scope 1 emissions over time.ab
Compared to the previous year (2022), Consun Pharmaceutical Group's Scope 1 emissions increased by 1.87%, suggesting that the company faced challenges in reducing emissions from its directly owned or controlled operations.a
In 2023, Consun Pharmaceutical Group reported Scope 2 greenhouse gas (GHG) emissions of 24,914.76 tCO₂e without specifying the calculation method.a
Since 2020, Consun Pharmaceutical Group's Scope 2 greenhouse gas (GHG) emissions (Unspecified Calculation Method) have increased by 61.38%, reflecting a rising long-term trend in Scope 2 emissions over time.ab
Compared to the previous year (2022), Consun Pharmaceutical Group's Scope 2 emissions (Unspecified Calculation Method) rose by 32.23% in 2023, suggesting that the company faced challenges in reducing emissions from purchased electricity and energya
In 2023, Consun Pharmaceutical Group reported its Scope 2 emissions using an unspecified methodology.a
In 2023, Consun Pharmaceutical Group reported Scope 1 greenhouse gas (GHG) emissions of 54,210.46 tCO₂e and total revenues of USD 364 millions. This translates into an emissions intensity of 148.75 tCO₂e per millions USD.a
In 2023, Consun Pharmaceutical Group reported a Scope 1 emissions intensity of 148.75 tCO₂e per millions USD. Compared to the peer group median of 23.6, this places the company above its industry benchmark, indicating it is less carbon-efficient than most competitors.a
In 2023, Consun Pharmaceutical Group ranked 24 out of 25 companies in its industry peer group, based on Scope 1 emissions intensity (measured in tCO₂e per millions USD).a
This places Consun Pharmaceutical Group among the least efficient performers, with one of the highest emissions intensities in its sector.a